[Retracted] The In Vitro Antimicrobial and Antibiofilm Activities of Lysozyme against Gram-Positive Bacteria

Table 1

The MICs (μg/mL) of various drugs and their combination with LYS against different species of clinical isolated GPB.

No.	Drugs	Isolates		Use alone	Combinations
					+10 μg/mL LYS	+30 μg/mL LYS
1	LZD	MRSA	31 ^a	1	1	1
			33	1	1	1
			62	1	1	1
		MRSE	61	1	1	1
			62	1	1	1
			63	1	1	1
		VREF	11	2	2	1
			12	1	1	1
			13	1	1	1
2	AMK	MRSA	31	1	1	1
			33	2	1	4
			62	2	4	4
		MRSE	61	<0.5	<0.5	<0.5
			62	2	2	2
			63	2	2	2
		VREF	11	>256	>256	>256
			12	>256	>256	>256
			13	>256	>256	>256
3	CRO/SBT	MRSA	31	>256	>256	>256
			33	32	32	16
			62	8	8	8
		MRSE	61	>32	>32	>32
			62	4	8	8
			63	16	16	32
		VREF	11	>256	>256	>256
			12	>32	>32	>32
			13	>32	>32	>32
4	CTX/SBT	MRSA	31	>256	>256	>256
			33	16	16	8
			62	8	8	8
		MRSE	61	>32	>32	>32
			62	>32	>32	>32
			63	8	8	4
		VREF	11	>256	>256	>256
			12	>32	>32	>32
			13	>32	>32	>32
5	PIP/SBT	MRSA	31	256	256	128
			33	16	16	8
			62	8	8	4
		MRSE	61	128	128	64
			62	32	32	16
			63	2	2	2
		VREF	11	>256	>256	>256
			12	>256	>256	>256
			13	>256	>256	>256
6	DOX	MRSA	31	0.5	0.5	0.5
			33	<0.0625	<0.0625	<0.0625
			62	2	2	2
		MRSE	61	<0.0625	<0.0625	<0.0625
			62	<0.0625	<0.0625	<0.0625
			63	1	1	1
		VREF	11	<0.0625	<0.0625	<0.0625
			12	8	8	4
			13	<0.0625	0.125	<0.0625
7	LVX	MRSA	31	8	8	8
			33	0.25	0.25	0.25
			62	0.5	0.5	0.5
		MRSE	61	16	16	8
			62	2	2	2
			63	8	8	8
		VREF	11	32	32	32
			12	>16	>16	>16
			13	>16	>16	>16
8	AK71	MRSA	31	64	64	32
			33	8	4	2
			62	2	4	<0.5
		MRSE	61	32	16	8
			62	<0.5	<0.5	<0.5
			63	1	<0.5	1
		VREF	11	>256	>256	>256
			12	128	128	128
			13	>256	>256	>256
9	IPM	MRSA	31	64	64	64
			33	0.5	0.5	0.5
			62	<0.125	<0.125	<0.125
		MRSE	61	16	2	0.5
			62	0.125	0.25	0.25
			63	1	1	1
		VREF	11	>256	>256	>256
			12	>32	>32	>32
			13	>32	>32	>32
10	AZM	MRSA	31	128	128	64
			33	>128	>128	>128
			62	>128	>128	>128
		MRSE	61	>128	>128	>128
			62	>128	>128	>128
			63	>128	>128	>128
		VREF	11	1	1	1
			12	>256	>256	>256
			13	>128	>128	>128

A number indicated the name of clinical isolates. MICs: minimum inhibitory concentrations; GPB: Gram-positive bacteria; MRSA: methicillin-resistant Staphylococcus aureus; MRSE: methicillin-resistant Staphylococcus epidermidis; VREF: vancomycin-resistant Enterococcus faecium; LYS: lysozyme; LZD: linezolid; AMK: amikacin; CRO/SBT: ceftriaxone/sulbactam; CTX/SBT: cefotaxime/sulbactam; PIP/SBT: piperacillin/sulbactam; DOX: doxycycline; LVX: levofloxacin; AK71: amoxicillin/clavulanate potassium 7 : 1; IPM: imipenem; AZM: azithromycin; –: not tested.